What top creators are saying about Anthropic(PRIVATE)— Page 2

Rapid reported revenue growth and substantial compute demand are counterbalanced by large losses, customer concentration, infrastructure commitments, and operational and liability risks. The valuation figure is an aim, not a confirmed IPO price.

Was reportedly seeking 1.5 gigawatts of Google TPU capacity through financing arranged with Blackstone. The host questioned its ability to meet the financial commitments and emphasized the infrastructure and power needs beyond chip purchases.

Revenue growth was described as extraordinary at 50% quarter over quarter, but reported revenue of $16.8 billion was below an $18 billion expectation. Speakers cautioned that growth may slow and investor expectations may be excessive.

The post argues Anthropic should remain private because investors may not accept a $1.5T–$2T IPO valuation, especially after the Meta Muse drop. Employee forward sales are raised as a possibility, not a recommendation.

Anthropic is described as growing rapidly, while considering a delayed IPO and potentially accepting a lower valuation than previously rumored. Revenue and compute projections remain uncertain.

Growth was described as slowing and market share as declining, while the reported cash-flow figures and potential IPO valuation were viewed with skepticism. One speaker still saw long-term potential.

Its Claude tools are used for software development, but no valuation, financial analysis, or investment recommendation is provided.

Open-source adoption could pressure the economics of closed-model developers if it grows faster than the overall AI market. No company-specific recommendation was given.

Reported revenue growth and adjusted profitability are unverified, while the planned valuation depends on sustaining rapid growth and delivering anticipated model-driven revenue acceleration.

Reported $16.8 billion in Q3 revenue, equivalent to a $67.2 billion annualized run rate, but growth was below some investors’ expectations. Customer concentration, competition, and anti-distillation measures are factors to monitor.

The potential Anthropic IPO is highlighted, but no valuation or timeframe is provided.

Cited as an AI company seeking substantial compute capacity; space-based data centers could eventually matter, but no investment recommendation or valuation assessment was provided.

The discussion raised concerns about slowing sequential growth, open-source competition, infrastructure spending, and the ability to make AI profitable. Any valuation and IPO plans remain uncertain.

A guest was bearish on Anthropic relative to competition from SpaceX/Grok and other AI platforms; speakers also questioned whether frontier-model companies can earn adequate returns without controlling compute.

Investor Day is framed as a volatility catalyst ahead of a possible IPO. A better-than-feared outcome could create a buying opportunity, but expectations and the company's outlook are unclear.

Revenue was reported at $16.8 billion versus an $18 billion expectation despite roughly 50% quarter-on-quarter growth. The speaker called growth exceptional but questioned whether expectations are too demanding and sustainable.

A potential IPO was described as possibly coming the following month, though it could be postponed if market conditions deteriorated; no valuation or investment recommendation was provided.

Reported Q3 revenue of $16.8 billion was below market expectations, and the discussion questioned whether its valuation and adjusted profitability are justified given excluded compute costs and possible capacity constraints.

Its annualized revenue run rate was estimated at about $70 billion. The discussion cautioned that data-center leasing and other infrastructure arrangements should be distinguished from customer demand for AI products.

Named as a potential competitor to Jev; no specific investment view was provided.

Hayes cited reported costs of $3 for every $1 of revenue in 2025 and said the company may need substantial debt financing. His concerns were about current profitability and investment economics.

Investor Day is a potential volatility catalyst, with high expectations and uncertain market reaction; no clear bullish or bearish signal was offered.

Identified in a report as a possible IREN partner, but the partnership and partner name were not confirmed.

Its safety-focused approach may appeal to users and policymakers, while subjective usage rules and public perceptions of its views on AI consciousness create reputational and governance risks. No investment recommendation or price target is given.

Named as a partner moving into traditional applications such as documents and office software, creating uncertainty about future competition with enterprise software providers.

The speaker said Anthropic had, in his view, not grown since July and considered stalled growth a serious warning sign, particularly in light of a possible very high IPO valuation.

Recognized as a leading AI lab, but panelists criticized its model-governance approach, expressing concerns about predictability, safety, and potential reputational or regulatory controversy.

Discussed as a major AI developer with potential demand for its tools, alongside uncertainty about AI capabilities and societal harms; no public ticker or confirmed price target is provided.

Customer concentration is a material revenue risk: two customers accounted for 25% of 2025 revenue, and Microsoft and Meta have reduced some Claude usage. Growth among enterprise customers could provide an opportunity, but investors should monitor large-customer spending and competition from in-house models.

Included in a speculative long-term forecast that AI labs may increasingly become biotechnology companies; no specific investment recommendation was made.

Potential IPO investors should weigh rapid revenue growth against substantial operating losses, long-term infrastructure commitments, customer and cloud-provider concentration, and uncertainty around government relations and continued product releases.

Named as a possible participant in AI-to-biotech convergence based on Huberman's prediction about leading AI firms' interest in the brain. No business plan, timeline, or investment recommendation was given.

Reports that Microsoft and Meta were reducing reliance on Claude Code raised possible cost savings for customers and concerns about competition and commoditization.

Reportedly considering an IPO before Thanksgiving, which could affect AI-sector sentiment. The discussion highlighted substantial spending, uncertain profitability, and funding needs.

Menlo identified Anthropic as a core AI investment and increased its position as strong results emerged; the discussion favors staged follow-on investment based on evidence.

Discussed as a frontier-model competitor that may expand into customers’ markets, including Figma’s, with partner-conflict, safety, and cost pressures noted.

The company is growing quickly but faces substantial operating losses, large and potentially inflexible compute commitments, competition from open-weight models, and governance and safety concerns. Investors should assess its ability to diversify revenue and sustain a competitive edge.

The proposed valuation was criticized as excessive in light of reported operating and net losses; the IPO expectations and valuation are unconfirmed.

Anthropic was reported as a potential IPO candidate and a major driver of AI infrastructure spending, while its competitive position and financial commitments remain risks.

The speaker discussed reports of a potential IPO before Thanksgiving and an approximately 84% prediction-market probability of an IPO by year-end. He viewed a major IPO as a possible sign that the AI boom could be nearing a speculative peak.

A potential IPO was discussed, possibly ahead of OpenAI; the investment outlook depends on revenue growth and the company's ability to retain market share amid open-source competition.

The discussion cites compute costs of about $1.60 per dollar of revenue, customer concentration, potentially plateauing revenue, and intensifying competition, while noting that compute constraints could be limiting demand.

Its early access models for Colossal and announced wet-lab work signal potential expansion of AI into biology, but no company-specific investment case or financial details are given.

Its announced wet-lab work was described as evidence that major AI companies view biology as an important application, while AI-generated biological claims still require laboratory validation.

The purported leaked filing is unconfirmed. Reported rapid revenue growth is accompanied by large operating losses, substantial infrastructure obligations, and customer concentration; the host said they had no direct exposure.

Mentioned in the AI-lab ecosystem and as the provider of Claude in Slack; no company-specific financial outlook or investment recommendation is given.

The host discusses its IPO filing, rapid revenue growth, and reported operating loss exceeding $8 billion in 2025, highlighting substantial infrastructure costs and uncertainty about post-IPO performance.

Reported high growth is accompanied by substantial losses, infrastructure commitments, and customer concentration; the purported filing is leaked and unverified, and no buy recommendation was given.

Discussed as a leading AI lab in the context of proposals to measure AI contributions to research and development and prepare for potential AI-related risks. No specific company outlook or investment recommendation was given.

Government-contract blacklisting and shifting political treatment create uncertainty and regulatory risk; no valuation or recommendation was provided.